Other

Suntory Limited

Shionogi Company Limited

Hisayuki Matsuo

Kenji Kangawa

Daiichi Pure Chemicals Co., Ltd.

Hasayuki Matsuo

Shoji Tanaka

Kensaku Mizuno

Masayasu Kojima

Naoto Minamino

Yoshiharu Minamitake

Hiroshi Hosoda

Kazuhiro Ohsuye

Kazuo Kitamura

Tanenao Eto

Katsuhiko Kitano

Yasunori Tawaragi

Takaharu Tanaka

Atsushi Izumi

Kayoko Fuchimura

Tetsuji Sudoh

Keiji Maekawa

Hiroshi Nakazato

Takehiro Oshima

Mayumi Furuya

Shinzo Oikawa

Yujiro Hayashi

Yasuo Kitajima

Kenji Kanagawa

Mitsutaka Isogai

Naoto Minamito

Mika Takashima

The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.

Modified ghrelin peptides

Modified gherlin peptides

Modified ghrelin polypeptides

A physiologically active polypeptide derived from human brain and a DNA fragment comprising the base sequence encoding the polypeptide are disclosed. The polypeptide possesses excellent smooth muscle relaxation activity, diuretic or natriuretic activity, and vasodepressor activity, and is thus useful as a medicine for curing circulation diseases, e.g. cardiac edema, nephric edema, hepatic edema, pulmonary edema, hypertension, congestive heat failure, and acute and chronic renal failure.

Physiologically active polypeptide and DNA

A C-terminal &agr;-amidating enzyme of and precursor thereof produced by a recombinant DNA technique; a DNA coding for the enzyme or precursor thereof; a plasmid containing the DNA; a host organism transformed with the plasmid; a process for production of the enzyme using the transformant; and a process for production of a C-terminal &agr;-amidated peptide using the enzyme.

Enzymatic production of a C-terminal &agr;-amidated peptide or protein

A C-terminal &agr;-amidating enzyme of,and precursor thereof produced by a recombinant DNA technique; a DNA coding for the enzyme or precursor thereof; a plasmid containing the DNA; a host organism transformed with the plasmid; a process for production of the enzyme using the transformant; and a process for production of a C-terminal &agr;-amidated peptide using the enzyme.

Recombinant C-terminal &agr;-amidating enzyme

The gene of a human CNP (human C-type natriuretic peptide), as well as the hCNP precursor protein that is encoded by said gene. The hCNP precursor is represented by the following amino acid sequence.

Human CNP gene and precursor protein

The gene and cDNA of a procine derived CNP (C-type natriuretic peptide), and a procine derived CNP precursor protein and derivatives thereof are disclosed. The proceine derivative CNP precursor is represented by the following amino acid sequence:

Porcine CNP gene and precursor protein

A cDNA coding for a rat derived CNP (rCNP: C-type natriuretic pepteide), and a rat derived CNP precursor protein and derivatives thereof are disclosed. The rat derived CNP precursor is represented by the following amino acid sequence.

Rat CNP complementary DNA and precursor protein

Adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.

Adrenomedullin

According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.

Antibodies to adrenomedullin

DNA encoding adrenomedullin

Growing community of inventors

Kobe, Japan

Hisayuki Matsuo